Profit

Will list German arm Syngene in next 12 months: Biocon

PUBLISHED ON: May 23, 2012 | Duration: 7 min, 11 sec

  
loading..
Kiran Mazumdar Shaw, Chairman of Biocon speaks about the Espirto Santo report that questions the company's accounting standards, Axi Corp, insulin business, Pfizer deal, Statin business, listing of German arm Syngene. She says that margins have improved after Axi Corp exit
ALSO WATCH
English vs Kannada: Regional Pride Or Modern Necessity?

................................ Advertisement ................................

................................ Advertisement ................................